Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8630 in adolescents with asthma
NCT07065331Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd8630 in asthma, sponsored by AstraZeneca. Primary endpoints: Area under the serum concentration-time curve from time zero to 24 hours, Maximum observed drug concentration at Day 9 and 1 more. Started Jun 2025; status: completed.
02
Drugs
azd8630
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07065331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065331.